Review
Published · Updated · 1 min read
Azelaic acid: risk management plan summary for Milenon gel
What it means for practice
The available description outlines risk minimization through prescribing and packaging information and ongoing pharmacovigilance. The absence of identified significant risks in the plan should not be interpreted as an absence of adverse reactions.
Summary
The available description of the risk management plan for Milenon gel, which contains azelaic acid, concerns its use for treating papulopustular acne and rosacea. It outlines the approach to risk minimization and continued monitoring of the medicine’s safety.
What the plan description states
According to the description, the plan currently identifies no significant risks or missing safety information. This conclusion is presented as consistent with existing data. However, the absence of identified significant risks in the plan should not be equated with an absence of possible adverse reactions during treatment.
Routine risk minimization measures include information in the instructions for medical use and on the packaging. Ongoing pharmacovigilance activities are also described as part of monitoring the safety of the gel.
The description emphasizes continuous monitoring and updating safety information to support the safe use of Milenon. This article is based on the available description; the original plan summary requires editorial verification.
Source
-
Міленон, гель, ТОВ “КУСУМ”, Україна.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
